BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance CutZacks Investment Research • 05/01/25
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/01/25
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales SoarInvestors Business Daily • 05/01/25
Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 04/30/25
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European UnionGlobeNewsWire • 04/15/25
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.Investors Business Daily • 04/10/25
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price TagSeeking Alpha • 04/09/25
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 04/02/25
Biopharma firms with foreign exposure face disruption as Trump's tariffs loomProactive Investors • 03/27/25
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall SquareGlobeNewsWire • 03/24/25
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?Zacks Investment Research • 03/14/25
BIIB Starts Felzartamab Phase III Study in AMR in Kidney TransplantZacks Investment Research • 03/12/25